ArticleArthritis research & therapy2022
A comprehensive profile of chemokines in the peripheral blood and vascular tissue of patients with Takayasu arteritis.
Article in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- The role of immune regulation in peripheral nerve regeneration: functions of inflammatory cells and cytokines.Frontiers in pharmacology · 2026Review
- CCL2/CCR2 signaling pathway in tumorigenesis and metastasis (Review).Oncology letters · 2025Review
- Insight Into the Role of NLRP3 Inflammasomes in Takayasu's Arteritis: Mechanisms and Targeted Pharmacotherapies.Reviews in cardiovascular medicine · 2025Review
- Evidence of Inflammatory Network Disruption in Chronic Venous Disease: An Analysis of Circulating Cytokines and Chemokines.Biomedicines · 2025Article
- Role of interleukin-16 in human diseases: a novel potential therapeutic target.Frontiers in immunology · 2025Review
- Identification and analysis of chemokine-related and NETosis-related genes in acute pancreatitis to develop a predictive model.Frontiers in genetics · 2024Article
- Cisplatin cycles treatment sustains cardiovascular and renal damage involving TLR4 and NLRP3 pathways.Pharmacology research & perspectives · 2023Article
- Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients.Cell reports. Medicine · 2023Article
- Monocyte subsets and monocyte-related chemokines in Takayasu arteritis.Scientific reports · 2023Article
- Arterial wall fibrosis in Takayasu arteritis and its potential for therapeutic modulation.Frontiers in immunology · 2023Review
- Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis.Diagnostics (Basel, Switzerland) · 2022Review
- Biomarker Changes and Molecular Signatures Associated with Takayasu Arteritis Following Treatment with Glucocorticoids and Tofacitinib.Journal of inflammation research · 2022Article
- Transcriptome profiling of abdominal aortic tissues reveals alterations in mRNAs of Takayasu arteritis.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTakayasu arteritis (TAK) is a chronic granulomatous large vessel vasculitis with multiple immune cells involved. Chemokines play critical roles in recruitment and activation of immune cells. This study aimed to investigate chemokine profile in the peripheral blood and vascular tissue of patients with TAK.
methodsA total of 58 patients with TAK and 53 healthy controls were enrolled. Chemokine array assay was performed in five patients with TAK and three controls. Chemokines with higher levels were preliminarily validated in 20 patients and controls. The validated chemokines were further confirmed in another group of samples with 25 patients and 25 controls. Their expression and distribution were also examined in vascular tissue from 8 patients and 5 controls. Correlations between these chemokines and peripheral immune cells, cytokines, and disease activity parameters were analyzed. Their serum changes were also investigated in these 45 patients after glucocorticoids and immunosuppressive treatment.
resultsPatients and controls were age and sex-matched. Twelve higher chemokines and 4 lower chemokines were found based on the chemokine array. After validation, increase of 5 chemokines were confirmed in patients with TAK, including CCL22, RANTES, CXCL16, CXCL11, and IL-16. Their expressions were also increased in vascular tissue of patients with TAK. In addition, levels of RANTES and IL-16 were positively correlated with peripheral CD3
conclusionsCCL22, RANTES, CXCL16, CXCL11, and IL-16 were identified as the major chemokines involved in the recruitment of immune cells in the vascular tissue of patients with TAK. Additionally, the persistently high levels of CCL22, CXCL11, and IL-16 observed after treatment indicate their role in vascular chronic inflammation or fibrosis and demonstrate the need for developing more efficacious treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.